Valeant revenue forecast fizzles as competition heats up; shares dip

(Reuters) - Valeant Pharmaceuticals on Wednesday gave a weaker-than-expected revenue forecast for 2018, as several of its major drugs face more competition from generics.

from Reuters: Business News http://ift.tt/2FEWqGb